Clinical Trial Update: Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial is planned to evaluate the combination of glumetinib with osimertinib for recurrent or metastatic non-small cell lung cancer with cla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Glumetinib
• Osimertinib (osimertinib)

Snippet

Sponsor: Shanghai JMT-Bio Inc. | Conditions: Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING